ADC Payload Platform Hexagon Bio specializes in discovering novel payloads for antibody-drug conjugates (ADCs) from microbial genomes, presenting a unique capability to supply next-generation payloads to biopharma partners pursuing oncology ADC programs.

Oncology Pipeline The company targets a broad range of solid tumors and hematologic malignancies with next-generation ADC candidates, offering potential collaboration on diverse oncology indications and payload mechanisms.

Strategic Collaborations Recent and ongoing partnerships, including joint ventures with Corteva for natural crop protections and an expanding Clinical Advisory Board for HEX-360, signal openness to co-development and monetization opportunities beyond pure biotech applications.

Leadership and Experience Key hires and seasoned leadership from successful programs (e.g., senior drug discovery leadership with Amgen) strengthen capabilities for rapid candidate progression, providing a credible partner for out-licensing or joint development.

Funding and Growth With substantial fundraising history and a multi-hundred-million-dollar funding level, Hexagon Bio is positioned to scale platform capabilities and accelerate partnerships, making it a compelling target for strategic investors and potential collaborators seeking accelerated commercialization.